Afatinib plus bevacizumab (a potent monoclonal antibody targeting VEGF) have reported positive treatment effect in patients with NSCLC after acquired resistance to EGFR–TKI.11 This evidence concerns the gene EGFR and non-small cell lung carcinoma.